2-(4-氰基苯氧基)-2-甲基丙酸 | 79925-16-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(4-氰基苯氧基)-2-甲基丙酸
• 英文名称: 2-(4-cyanophenoxy)-2-methylpropanoic acid
• 英文别名: 2-(4-cyanophenoxy)-2-methylpropionic acid；2-(4-cyanophenoxy)-2-methyl propionic acid
• CAS: 79925-16-9
• 化学式: C₁₁H₁₁NO₃
• mdl: MFCD00084986
• 分子量: 205.213
• InChiKey: GBGYSMXMZDBILF-UHFFFAOYSA-N

物化性质

• 熔点：
  118-120 °C
• 沸点：
  381.3±17.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  70.3
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26,S36/37/39,S45
• 危险类别码：
  R20/21/22,R36/37/38
• 海关编码：
  2926909090

SDS

Name:	2-(4-Cyanophenoxy)-2-methylpropanoic acid 80
Synonym:
CAS:	79925-16-9

Section 1 - Chemical Product MSDS Name:2-(4-Cyanophenoxy)-2-methylpropanoic acid 80
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
79925-16-9	2-(4-Cyanophenoxy)-2-methylpropanoic a	80<90%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 79925-16-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H11NO3
Molecular Weight: 205.21

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 79925-16-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-(4-Cyanophenoxy)-2-methylpropanoic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: NITRILES, SOLID, TOXIC, N.O.S.*
Hazard Class: 6.1
UN Number: 3276
Packing Group: III
IMO
Shipping Name: NITRILES, TOXIC, N.O.S.
Hazard Class: 6.1
UN Number: 3276
Packing Group: III
RID/ADR
Shipping Name: NITRILES, TOXIC, N.O.S.
Hazard Class: 6.1
UN Number: 3276
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 79925-16-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 79925-16-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 79925-16-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(4-氰基苯氧基)-2-甲基丙酸 在 氢氧化钾 、 sodium hydroxide 、 双氧水 、 溴 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 0.5h， 生成 2-[4-[(3,4-二氯苯基)氨基甲酰氨基]苯氧基]-2-甲基丙酸
  参考文献：
  名称：

  2- [4-[[[（（芳基氨基）羰基]氨基]苯氧基] -2-甲基丙酸对血红蛋白对氧的亲和力的合成和影响研究：结构-活性关系。

  摘要：

  合成了一系列2- [4-[[[[（（取代-苯基）氨基]羰基]氨基]苯氧基] -2-甲基丙酸和其他取代的苯氧基乙酸，并测试了它们降低血红蛋白对氧的亲和力的能力。发现2- [4-[[[（（3,4,5-三氯苯基）氨基]羰基]氨基]苯氧基] -2-甲基丙酸是已知的最有效的化合物。讨论了合成化合物的构效关系。

  DOI：

  10.1021/jm00130a021
• 作为产物：
  描述：

  4-羟基苯甲腈 在 potassium carbonate 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 16.17h， 生成 2-(4-氰基苯氧基)-2-甲基丙酸
  参考文献：
  名称：

  新型，有效，选择性，口服生物利用腺苷A 2A受体拮抗剂的设计，合成及其生物学评价

  摘要：

  我们对7位-甲氧基-4-吗啉代-苯并噻唑衍生物在2位上具有特征性的芳氧基-2-甲基丙酰胺部分的初步构效关系研究导致将化合物25鉴定为有效且选择性的A 2A腺苷受体（A 2A AdoR ）具有合理ADME和药代动力学特性的拮抗剂。但是，固有溶解性差和口服生物利用度低至中等，使得该系列不适合进一步开发。使用基于结构的药物设计方法进行的进一步优化导致发现了有效和选择性的腺苷A 2A受体拮抗剂在苯并噻唑支架的2位带有取代的1-甲基环己基甲酰胺基，具有更好的溶解度和口服生物利用度。化合物41和49在体外ADME特性方面表现出许多积极的特性。两种化合物在大鼠中均表现出良好的药代动力学性质，口服生物利用度分别为63％和61％。此外，化合物49在帕金森氏病的6-OHDA损伤的大鼠模型中显示出口服功效。

  DOI：

  10.1021/acs.jmedchem.6b01584

文献信息

• Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents
  作者：Ramnarayan S. Randad、Mona A. Mahran、Ahmed S. Mehanna、Donald J. Abraham

  DOI：10.1021/jm00106a041

  日期：1991.2

  included 4-[[(aryloyl)amino]methyl]phenoxy, 4-(arylacetamido)phenoxy, and 4-[[(arylamino)carbonyl]methyl]phenoxy. A total of 20 compounds were synthesized and tested. Structure-activity relationships are presented. Several of the new compounds were found to be strong allosteric effectors of hemoglobin. The two most active compounds are 2-[4-[[(3,5-dichloroanilino)carbonyl]-methyl]phenoxy]- 2-methylpropionic

  制备了2-（芳氧基）-2-甲基丙酸的三个异构体系列，并研究了它们降低人血红蛋白A的氧亲和力的能力。异构体芳氧基包括4-[[[（芳基）氨基]甲基]苯氧基，4 -（芳基乙酰氨基）苯氧基和4-[[[（芳基氨基）羰基]甲基]苯氧基。总共合成和测试了20种化合物。提出了构效关系。发现几种新化合物是血红蛋白的强变构效应物。两种最具活性的化合物是2- [4-[[（（3,5-二氯苯胺基）羰基]-甲基]苯氧基] -2-甲基丙酸和相应的3,5-二甲基衍生物。后两种化合物已在同一试验中与其他已知的强变构效应子进行了比较，并显示出更高的活性。与全血一起孵育时，这两种化合物的氧平衡曲线也都向右移动。新化合物可能在需要或受益于氧气供应逆转的临床或生物学领域（例如，缺血，中风，肿瘤放疗，储血，血液替代品等）中可能引起关注。它们在结构上还与几种市售的抗血脂药有关。
• MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN
  申请人：AbbVie S.à.r.l.

  公开号：US20170305891A1

  公开（公告）日：2017-10-26

  The present invention provides for compounds of formula (I) wherein R 1 , m, Z, G 1 , R 2 , and R 3 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

  本发明提供了以下式（I）的化合物，其中R1、m、Z、G1、R2和R3具有规范中定义的任何值，以及其药学上可接受的盐，这些化合物可用作治疗由CFTR介导和调节的疾病和症状的药物，包括囊性纤维化、Sjögren综合征、胰腺功能不全、慢性阻塞性肺病和慢性阻塞性气道疾病的药物。还提供了由一个或多个式（I）化合物组成的药物组合物。
• Amido compounds and their use as pharmaceuticals
  申请人：Yao Wenqing

  公开号：US20060009471A1

  公开（公告）日：2006-01-12

  The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.

  本发明涉及11-β羟基类固醇脱氢酶类型1的抑制剂，矿皮质激素受体（MR）的拮抗剂，以及其药物组合物。本发明的化合物可用于治疗与11-β羟基类固醇脱氢酶类型1的表达或活性相关的各种疾病，以及与醛固酮过量相关的疾病。
• Method of synthesis and novel compounds for pharmaceutical uses
  申请人：Montefiore Medical Center

  公开号：US04921997A1

  公开（公告）日：1990-05-01

  The present invention is concerned with a process for the synthesis of substituted arylureidophenexymethyl propionic acids and an analogous benzamides series of compounds which have activity in the dissociation of oxygen from hemoglobin. In addition, the process may be utilized to prepare compounds which are known.

  本发明涉及一种合成取代芳基脲基苯甲基丙酸和类似苯甲酰胺系列化合物的过程，这些化合物具有从血红蛋白中解离氧的活性。此外，该过程可用于制备已知化合物。
• [EN] PROCESS FOR PREPARING A THIALZOLE PPAR-LIGAND AND POLYMORPHS THEREOF<br/>[FR] PROCEDE RELATIF A L'ELABORATION DE LIGAND DE RECEPTEUR PPAR A BASE DE THIAZOLE, Y COMPRIS SES POLYMORPHES
  申请人：GLAXO GROUP LTD

  公开号：WO2002096893A1

  公开（公告）日：2002-12-05

  A method of preparing a compound of formula (I), and pharmaceutically acceptable salts and solvates thereof. Polymorphs of this compound and their use as PPAR ligands are also disclosed.

  一种制备公式（I）化合物及其药学上可接受的盐和溶剂化物的方法。还公开了该化合物的多晶形态及其作为PPAR配体的用途。